Corporate

CLINUVEL
Posted by CLINUVEL
August 26, 2021

Corporate Presentation - FY2021 Results

Melbourne, Australia, 26 August 2021 ASX: XETRA-DAX: NASDAQ INTERNATIONAL DESIGNATION: CUV UR9...

Read More
CLINUVEL
Posted by CLINUVEL
August 26, 2021

Appendix 4E and Preliminary Financial Report

Melbourne, Australia, 26 August 2021 ASX: XETRA-DAX: NASDAQ INTERNATIONAL DESIGNATION: CUV UR9...

Read More
CLINUVEL
Posted by CLINUVEL
August 26, 2021

CLINUVEL Delivers Record Revenues and Profit

Melbourne, Australia, 26 August 2021 ASX: XETRA-DAX: NASDAQ INTERNATIONAL DESIGNATION: CUV UR9...

Read More
CLINUVEL
Posted by CLINUVEL
August 26, 2021

Dividend/Distribution - CUV

Melbourne, Australia, 26 August 2021 ASX: XETRA-DAX: NASDAQ INTERNATIONAL DESIGNATION: CUV UR9...

Read More
CLINUVEL
Posted by CLINUVEL
July 14, 2021

Insider Insights III: Willem Blijdorp - Challenges & the Future

CLINUVEL today launches the third and final part of the Insider Insights...

Read More
CLINUVEL
Posted by CLINUVEL
July 7, 2021
CLINUVEL
Posted by CLINUVEL
June 30, 2021

Insider Insights: Willem Blijdorp - Chair of The CLINUVEL Group

CLINUVEL today launched the Insider Insights series, featuring Chair Willem Blijdorp on...

Read More
CLINUVEL
Posted by CLINUVEL
June 4, 2021

CLINUVEL Presentation to Jefferies Healthcare Conference

Melbourne, Australia, 04 June 2021 ASX: XETRA-DAX: NASDAQ INTERNATIONAL DESIGNATION: CUV UR9...

Read More
CLINUVEL
Posted by CLINUVEL
April 26, 2021

Wilsons Initiates Research Coverage of CLINUVEL

Melbourne, Australia, 26 April 2021 ASX: XETRA-DAX: NASDAQ INTERNATIONAL DESIGNATION: CUV UR9...

Read More
CLINUVEL
Posted by CLINUVEL
April 11, 2021

CLINUVEL Strategic Update II

Melbourne, Australia, 12 April 2021 CLINUVEL today announced its second Strategic Update,...

Read More
CLINUVEL
Posted by CLINUVEL
March 24, 2021

Media Release - CLINUVEL Expands DNA Repair Program

SCENESSE® (afamelanotide 16mg) to be evaluated in xeroderma pigmentosum variant (XP-V) CLINUVEL...

Read More
CLINUVEL
Posted by CLINUVEL
March 24, 2021

SCENESSE® To Be Evaluated in Xeroderma Pigmentosum Variant (XPV)

CLINUVEL today announced that it has reached agreement with clinical and academic...

Read More
CLINUVEL
Posted by CLINUVEL
February 11, 2021

SCENESSE® Granted Market Access In Israel

CLINUVEL today announced that SCENESSE® (afamelanotide 16mg) has been added to the...

Read More
CLINUVEL
Posted by CLINUVEL
January 12, 2021

H.C. Wainwright Bioconnect Conference 2021

12 January 2021 https://vimeo.com/clinuvel/review/499638631/b90c97ddb9 Download Presentation & Speaker Notes

Read More
CLINUVEL
Posted by CLINUVEL
December 24, 2020

Appendix 3G

Notification of issue, conversion or payment up of equity & securities. Download...

Read More
We use cookies to give you the best experience.